Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule
- PMID: 3157661
- DOI: 10.1007/BF00176825
Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule
Abstract
A phase I trial of chlorozotocin was completed for a weekly times four dose schedule repeated every 8 weeks. Thrombocytopenia was the acute dose limiting toxicity. Nausea and vomiting were moderate to severe and dose related. Two cases of possible drug related irreversible nephrotoxicity were seen. Transient elevations of serum creatinine and mild proteinuria were noted. Also, transient elevations in SGOT were observed. One patient with a carcinoid tumor had a 60% reduction in his 5HIAA level after one course of therapy. The recommended dose for phase II clinical studies of chlorozotocin is 40 mg/m2 IV weekly for four weeks, repeated every 8 weeks.
Similar articles
-
Phase I evaluation of chlorozotocin: single dose every six weeks.Cancer. 1980 Dec 1;46(11):2365-8. doi: 10.1002/1097-0142(19801201)46:11<2365::aid-cncr2820461109>3.0.co;2-t. Cancer. 1980. PMID: 6449279
-
Phase I trial of chlorozotocin.Cancer Treat Rep. 1979 Jan;63(1):17-20. Cancer Treat Rep. 1979. PMID: 154363 Clinical Trial.
-
Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.Eur J Cancer (1965). 1981 Mar;17(3):337-43. doi: 10.1016/0014-2964(81)90125-0. Eur J Cancer (1965). 1981. PMID: 6455296 No abstract available.
-
A phase II study of chlorozotocin in advanced large bowel carcinoma. A cooperative study between two institutions.Am J Clin Oncol. 1984 Oct;7(5):507-11. doi: 10.1097/00000421-198410000-00022. Am J Clin Oncol. 1984. PMID: 6239538 Clinical Trial.
-
Chlorozotocin.IARC Monogr Eval Carcinog Risks Hum. 1990;50:65-75. IARC Monogr Eval Carcinog Risks Hum. 1990. PMID: 2149865 Free PMC article. Review. No abstract available.